Alamar Biosciences (NASDAQ: ALMR) completes $219.9M IPO and updates bylaws
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.
Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.
Positive
- Substantial IPO capital raise: Alamar Biosciences completed an IPO of 12,937,500 shares at $17.00 per share, including the full underwriters’ option, for approximately $219.9 million in aggregate gross proceeds before underwriting discounts and offering expenses.
Negative
- None.
Insights
Alamar’s IPO raises about $219.9M and activates its post‑IPO governance structure.
Alamar Biosciences, Inc. completed an IPO of 12,937,500 common shares at $17.00 per share, including 1,687,500 shares from the underwriters’ option. This produced aggregate gross proceeds of approximately $219.9 million before underwriting discounts and offering expenses.
Alongside the IPO closing on April 20, 2026, the company’s amended and restated certificate of incorporation and bylaws became effective, reflecting terms previously approved by the board and stockholders. These documents define Alamar’s public‑company governance structure, which will guide board authority, shareholder rights, and procedural rules.
Overall, this event combines a substantial primary capital raise with the formal transition to a listed, Delaware‑incorporated public company under Nasdaq trading symbol ALMR. Subsequent periodic reports are expected to provide detail on net proceeds after fees and how the new capital is deployed.
8-K Event Classification
3 items: 5.03, 8.01, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
IPO shares sold: 12,937,500 shares
Underwriters’ option shares: 1,687,500 shares
IPO price: $17.00 per share
+2 more
5 metrics
IPO shares sold
12,937,500 shares
Aggregate common stock sold in IPO, including underwriters’ option
Underwriters’ option shares
1,687,500 shares
Additional shares from full exercise of underwriters’ option
IPO price
$17.00 per share
Price to the public for each common share in the IPO
Gross IPO proceeds
approximately $219.9 million
Aggregate gross proceeds before underwriting discounts and expenses
IPO closing date
April 20, 2026
Date Alamar Biosciences completed its initial public offering
Key Terms
initial public offering, amended and restated certificate of incorporation, amended and restated bylaws, underwriters’ option, +1 more
5 terms
initial public offering financial
"In connection with the closing of the initial public offering (the “IPO”) of shares of common stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
amended and restated certificate of incorporation regulatory
"the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”)"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
amended and restated bylaws regulatory
"the Company adopted amended and restated bylaws (the “Restated Bylaws”)"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
underwriters’ option financial
"which includes the exercise in full of the underwriters’ option to purchase an additional 1,687,500 shares"
An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.
aggregate gross proceeds financial
"The aggregate gross proceeds from the IPO ... was approximately $219.9 million"
Aggregate gross proceeds are the total amount of money a company expects to receive from a securities offering or financing before any fees, expenses or deductions are taken out. For investors, this number shows the scale of new capital entering the business—like the size of a fuel tank refill—and helps gauge how much cash will be available to pay debts, fund growth or dilute existing ownership.
FAQ
What did Alamar Biosciences (ALMR) announce regarding its IPO?
Alamar Biosciences completed its initial public offering of common stock. The company sold 12,937,500 shares, including 1,687,500 from the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in aggregate gross proceeds before underwriting discounts and offering expenses.
How much money did Alamar Biosciences (ALMR) raise in gross proceeds from the IPO?
The IPO generated approximately $219.9 million in aggregate gross proceeds. This figure is calculated before deducting underwriting discounts, commissions, and estimated offering expenses payable by the company and is based on selling 12,937,500 shares at $17.00 per share.
Did the underwriters exercise their option in the Alamar Biosciences (ALMR) IPO?
Yes, the underwriters’ option was exercised in full. The IPO total of 12,937,500 common shares includes 1,687,500 shares issued pursuant to the full exercise of the underwriters’ option to purchase additional shares at the $17.00 offering price.
What corporate governance changes did Alamar Biosciences (ALMR) implement with its IPO?
Alamar adopted an amended and restated certificate of incorporation and bylaws. These Restated Certificate and Restated Bylaws, previously approved by the board and stockholders, became effective immediately prior to the IPO closing on April 20, 2026, establishing its post‑IPO governance framework.
On which exchange is Alamar Biosciences (ALMR) listed and what is its trading symbol?
Alamar Biosciences’ common stock trades on The Nasdaq Stock Market LLC. The company’s common shares, with a par value of $0.0001 per share, are listed under the trading symbol ALMR following completion of its initial public offering.